MiR-27a Modulates Radiosensitivity of Triple-Negative Breast Cancer (TNBC) Cells by Targeting CDC27

被引:0
|
作者
Ren, Yong-qiang [1 ]
Fu, Fengkui [2 ]
Han, Jianjun [3 ]
机构
[1] Cent Hosp Yishui, Clin Lab, Linyi, Shandong, Peoples R China
[2] Peoples Hosp Binzhou, Dpartment Radiol, Binzhou, Shandong, Peoples R China
来源
MEDICAL SCIENCE MONITOR | 2015年 / 21卷
关键词
Apc3; Subunit; Anaphase-Promoting Complex-Cyclosome; MicroRNAs; Radiotherapy; Adjuvant; Triple Negative Breast Neoplasms; ANAPHASE-PROMOTING COMPLEX; PROTEIN; EXPRESSION; MECHANISM; APOPTOSIS; PATHWAYS; SURVIVAL;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: MiR-27a is significantly overexpressed in triple-negative breast cancer (TNBC). However, the exact biological function of MiR-27a in TNBC is not fully understood. In this study, we verified miR-27a expression in TNBC cells and explored how its overexpression modulates radiosensitivity of the cells. Material/Method: qRT-PCR analysis was performed to study miR-27a expression in TNBC lines MDA-MB-435 and MDA-MB-231 and in normal human breast epithelial cell line MCF10A. Dual luciferase assay was performed to verify a putative downstream target of miR-27a, CDC27. CCK-8 assay was used to assess the influence of miR-27a-CDC27 axis on cell proliferation under irradiation (IR) treatment. Results: We confirmed significantly higher miR-27a expression in 2 TNBC cell lines - MDA-MB-435 and MDA-MB-231 - than in human breast epithelial cell line MCF10A. miR-27a could modulate proliferation and radiosensitivity of TNBC cells. CDC-27 is a direct target of miR-27a and its downregulation conferred increased radioresistance of the cells. Conclusions: The miR-27a-CDC27 axis might play an important role in modulating response to radiotherapy in TNBC cells. Testing miR-27a expression might be a useful way to identify a subgroup of patients who will benefit from an IR-based therapeutic approach.
引用
收藏
页码:1297 / 1303
页数:7
相关论文
共 50 条
  • [21] Targeting Triple-Negative Breast Cancer
    Saljoughian, Manouchehr
    US PHARMACIST, 2020, 45 (10) : 6 - 8
  • [22] Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
    Jung Ok Lee
    Min Ju Kang
    Won Seok Byun
    Shin Ae Kim
    Il Hyeok Seo
    Jeong Ah. Han
    Ji Wook Moon
    Ji Hae Kim
    Su Jin Kim
    Eun Jung Lee
    Serk In Park
    Sun Hwa Park
    Hyeon Soo Kim
    Breast Cancer Research, 21
  • [23] Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
    Lee, Jung Ok
    Kang, Min Ju
    Byun, Won Seok
    Kim, Shin Ae
    Seo, Il Hyeok
    Han, Jeong Ah
    Moon, Ji Wook
    Kim, Ji Hae
    Kim, Su Jin
    Lee, Eun Jung
    Park, Serk In
    Park, Sun Hwa
    Kim, Hyeon Soo
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [24] Chemokine network between triple-negative breast cancer (TNBC) and non-TNBC cells.
    Gibbs, Carla
    Ignacio, Rosa
    Hyeong, Choi
    Son, Deok-Soo
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2018, 27 (07) : 88 - 89
  • [25] Subtyping of triple-negative breast cancer (TNBC): A cohort study
    Thomssen, Christoph
    Hartung, Caroline
    Porsch, Martin
    Stuckrath, Kathrin
    Buchmann, Jorg
    Kantelhardt, Eva J.
    Vetter, Martina
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Involvement of proinflammatory chemokines in triple-negative breast cancer (TNBC)
    Ignacio, Rosa Mistica C.
    Gibbs, Carla
    Lee, Eun-Sook
    Son, Deok-Soo
    CANCER RESEARCH, 2016, 76
  • [27] Updates on Targeted Therapy for Triple-Negative Breast Cancer (TNBC)
    Noor Z.S.
    Master A.
    Current Breast Cancer Reports, 2018, 10 (4) : 282 - 288
  • [28] Information preferences of women with triple-negative breast cancer (TNBC).
    Swiger, Kathleen Dickerson
    Sendecki, Jocelyn A.
    Guglielmino, Janine E.
    Rugo, Hope S.
    Domchek, Susan M.
    Anders, Carey K.
    Stricker, Carrie Tompkins
    Nelson, Hillary C. M.
    Hanson, Arin Ahlum
    Dinerman, Hayley
    Henry, Catherine Creme
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Characterization of a novel lipase inhibitor targeting high cancer stemness in triple-negative breast cancer (TNBC)
    Grundmann, Hannah
    Bozzetti, Theresa
    On, Jasmin
    Kulik, Andrea
    Niederacher, Dieter
    Neubauer, Hans
    Fehm, Tanja
    Esser, Knud
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 257 - 257
  • [30] mir-218-2 promotes glioblastomas growth, invasion and drug resistance by targeting CDC27
    Feng, Zhuoying
    Zhang, Luping
    Zhou, Junchen
    Zhou, Shuai
    Li, Li
    Guo, Xuyan
    Feng, Guoying
    Ma, Ze
    Huang, Wenhua
    Huang, Fei
    ONCOTARGET, 2017, 8 (04) : 6304 - 6318